PATENT CLAIM ANALYSIS

Application Number: 15895055
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-06
Patent Classification: ["424", "173100"]

Abstract:
Anti-BAFFR antibodies are formulated as lyophilisate or liquid formulation. The lyophilisates can be reconstituted to give a solution with a high concentration of the antibody active ingredient for delivery to a patient without high levels of antibody aggregation. The lyophilisate can be reconstituted with an aqueous reconstituent to provide an aqueous composition in which the antibody has a concentration of at least 50 mg/ml. The lyophilisate or aqueous pharmaceutical composition may include one or more of a sugar, a buffering agent, a surfactant and/or a free amino acid.

Claim (Index 9):
The method of  claim 1 , wherein said formulation is prepared from an aqueous formulation having a pH of 6.5 and comprising\n (i) an anti-BAFFR antibody wherein the antibody has a concentration of 50 mg/ml, and wherein said anti-BAFFR antibody includes heavy chain CDR1, CDR2 and CDR3 of SEQ ID NOs 3, 4 and 5 respectively, and light chain CDR1, CDR2 and CDR3 of SEQ ID NOs: 6, 7 and 8, (ii) 90 mM sucrose as a stabilizer, (iii) 7 mM histidine as a buffering agent, (iv) 0.02% polysorbate 80 as a surfactant, and (v) 17 mM arginine-HCl.

Metadata:
- Claim Count in Document: 14.0
- Percentile: 88.0
- Lexical Diversity: 1.59322
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['13991984', '13912355', '14942388', '15881195', '14114835']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7396178495591916
- 35 USC 102 Novelty (BERT): 0.6132407022246159
- Combined Prediction Score: 0.7269801348257341
- Mean Citation Score: 492.277956
- Max Citation Score: 578.80133
- Similarity Product: 480.2669247532916

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test